Mayo Clinic’s Multiple Myeloma Clinical Trial Closes Early Due to Significantly Superior Results of Comparative Treatment

ROCHESTER, Minn. -- Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone. >>> Discuss This Story